Dr. Abbey Discusses the New Era of Geographic Atrophy Management
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a three-part special report video series by Ophthalmology Times that examined the evolving treatment landscape for geographic atrophy (GA). What is Geographic Atrophy?
read more
Dr. Abbey Presented on Retinal Sustained Drug Delivery Research at Retina World Congress
At the recently held Retina World Congress 2026 meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented on the evolving clinical trial landscape for sustained drug delivery in retinal disease. Dr.
read more Dr. Abbey Discusses Retinal Vein Occlusion as a Marker of Systemic Risk
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast to discuss “Retinal Vein Occlusion as a Marker of Systemic Risk.” This was the third episode he contributed to their “Eye
read more Dr. Abbey Discusses Retinal Vein Occlusion on ReachMD Podcast
Texas Retina’s Ashkan Abbey, MD, recently appeared on the ReachMD podcast as part of their “Spotlight on Retinal Vein Occlusion” series. In the first episode of this series, Dr. Abbey discusses distinguishing urgent
read more Dr. Abbey Publishes Case Report on New Approach to Treating Chronic Postoperative Cystoid Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently collaborated with colleagues from the Department of Ophthalmology at University of Texas Southwestern Medical Center in Dallas, to publish a case report in Retinal Cases &
read more Dr. Abbey Discusses New Treatment for Macular Telangiectasia Type 2
At AAO 2025, the American Academy of Ophthalmology’s annual meeting, Texas Retina’s Dr. Ashkan Abbey moderated a case-based roundtable discussion about the evolving landscape of macular telangiectasia (MacTel) type 2 care, including
read more
Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema
On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic
read more
Dr. Ashkan Abbey Presented at the American Academy of Ophthalmology Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented, taught and served as a panelist at AAO 2025, the American Academy of Ophthalmology’s annual meeting held in Orlando, Florida, October 18-20, 2025. Highlights of
read more Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more Dr. Abbey Delivered On-Demand Presentation About the PHOTON DME Study for ASRS 2025 Meeting
On behalf of the PHOTON study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered an on-demand presentation titled “Differential Anatomic Response to Aflibercept 8 mg vs 2 mg During Matched Dosing Phase
read more